FY2024 Earnings Forecast for Sanofi Issued By Zacks Research

Sanofi (NASDAQ:SNY) – Investment analysts at Zacks Research boosted their FY2024 earnings estimates for shares of Sanofi in a research report issued to clients and investors on Wednesday, November 13th. Zacks Research analyst K. Shah now expects that the company will post earnings of $4.31 per share for the year, up from their prior estimate of $4.12. The consensus estimate for Sanofi’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Sanofi’s Q4 2024 earnings at $0.84 EPS, Q1 2026 earnings at $1.17 EPS and Q2 2026 earnings at $1.16 EPS.

A number of other equities analysts also recently commented on the stock. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $47.97 on Monday. The stock’s 50-day moving average is $54.65 and its two-hundred day moving average is $52.23. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $121.74 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the company earned $2.55 EPS. Sanofi’s revenue was up 12.3% on a year-over-year basis.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SNY. POM Investment Strategies LLC acquired a new stake in Sanofi during the 2nd quarter valued at $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi in the 3rd quarter valued at $29,000. Concord Wealth Partners grew its position in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. Arrow Financial Corp acquired a new position in Sanofi in the second quarter valued at $35,000. Finally, Fortitude Family Office LLC increased its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.